http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 16:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Mock+James+M/26599210.html si-local-file:///var/storage/secattach/20260603/26599210.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Mock+James+M/26599210.html Wed, 03 Jun 2026 16:22:00 -0400 MRNA O.39449410 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Mock+James+M/26599210.html si-local-file:///var/storage/secattach/20260603/26599210.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Mock+James+M/26599210.html Wed, 03 Jun 2026 16:22:00 -0400 MRNA O.39449410 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Klinger+Shannon+Thyme/26599153.html si-local-file:///var/storage/secattach/20260603/26599153.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Klinger+Shannon+Thyme/26599153.html Wed, 03 Jun 2026 16:19:00 -0400 MRNA O.39449410 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Klinger+Shannon+Thyme/26599153.html si-local-file:///var/storage/secattach/20260603/26599153.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Klinger+Shannon+Thyme/26599153.html Wed, 03 Jun 2026 16:19:00 -0400 MRNA O.39449410 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Hoge+Stephen/26599072.html si-local-file:///var/storage/secattach/20260603/26599072.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Hoge+Stephen/26599072.html Wed, 03 Jun 2026 16:16:00 -0400 MRNA O.39449410 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Hoge+Stephen/26599072.html si-local-file:///var/storage/secattach/20260603/26599072.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Moderna%2C+Inc.+++++++++++++For%3A+Jun+01++Filed+by%3A+Hoge+Stephen/26599072.html Wed, 03 Jun 2026 16:16:00 -0400 MRNA O.39449410 http://www.streetinsider.com/Trader+Talk/Moderna+%28MRNA%29+sees+strong+intraday+gains/26598126.html <p>Moderna (NASDAQ: MRNA) is seeing strong intraday gains</p><ul><li>shares +6.6%</li><li>it is unclear the driver</li></ul> http://www.streetinsider.com/Trader+Talk/Moderna+%28MRNA%29+sees+strong+intraday+gains/26598126.html Wed, 03 Jun 2026 14:14:41 -0400 MRNA http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Press+Releases/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html <p>AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YACQHg4PypDB2_ntAGnkX8xPzHpTEk3itUBM6rUMdg6qhiIGG14V-nrpF7iOWpufVnBZUuOEBoSEK8zv8IMX-aFxdncbvJFLnIwXJ_b6lNxSGlkLoACuu05ew9bHE4JTppN5h18mKHYGUasXJZqtaKKfU_7r3CMfnhpes6t-xlxrO5uXcdkx2lmtBUQUpmEaFfVKSJiHYngrtdwsUTSpFcWw5Q4nmlUtC7FH04Fdh7bWT3B3E9sFZyjhg-rXK9e6eyb2wUHekiIVoL-82WWXslssNnJiUYrO_-EjO5vRyDzOFPXnABzoPmiqIK-ounSo" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc. http://www.streetinsider.com/Globe+Newswire/Platform+Biotech+Models+Draw+Investor+Eyes+as+Drug-Delivery+Markets+Head+Toward+%24410+Billion/26595903.html Wed, 03 Jun 2026 08:30:00 -0400 MRNA MRNA RVMD RVMD SRPT SRPT http://www.streetinsider.com/Press+Releases/Moderna+to+Present+at+Upcoming+Conference+in+June+2026/26587225.html <p><strong id="dateline">CAMBRIDGE, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 2, 2026 / </strong>Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:</p><p>Goldman Sachs 47^th Annual Global Healthcare Conference 2026, on Tuesday, June 9^th at 3:20 p.m. ET</p><p>A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at <a rel="nofollow" href="https://pr.report/9osrdGtP">investors.modernatx.com</a>.</p><p>A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.</p><p><strong>About Moderna</strong></p><p>Moderna is a pioneer and leader in the field of mRNA medicine. http://www.streetinsider.com/Press+Releases/Moderna+to+Present+at+Upcoming+Conference+in+June+2026/26587225.html Tue, 02 Jun 2026 07:00:00 -0400 MRNA http://www.streetinsider.com/ACCESS+Newswire/Moderna+to+Present+at+Upcoming+Conference+in+June+2026/26587225.html <p><strong id="dateline">CAMBRIDGE, MA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 2, 2026 / </strong>Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:</p><p>Goldman Sachs 47^th Annual Global Healthcare Conference 2026, on Tuesday, June 9^th at 3:20 p.m. ET</p><p>A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at <a rel="nofollow" href="https://pr.report/9osrdGtP">investors.modernatx.com</a>.</p><p>A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.</p><p><strong>About Moderna</strong></p><p>Moderna is a pioneer and leader in the field of mRNA medicine. http://www.streetinsider.com/ACCESS+Newswire/Moderna+to+Present+at+Upcoming+Conference+in+June+2026/26587225.html Tue, 02 Jun 2026 07:00:00 -0400 MRNA http://www.streetinsider.com/FDA/Moderna+and+Merck+report+sustained+melanoma+treatment+benefits+at+5+years/26579600.html <p>Moderna Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK) announced five-year follow-up data from their Phase 2b melanoma study showing sustained benefits for their combination cancer treatment. The study evaluated intismeran autogene plus Keytruda versus Keytruda alone in patients with high-risk melanoma following surgery.</p> <p>At a median follow-up of 60.3 months, the combination treatment reduced the risk of cancer recurrence or death by 49% compared to Keytruda alone. The combination also reduced the risk of distant cancer spread or death by 59%. An exploratory analysis showed an encouraging trend toward improved overall survival, though the confidence interval included the possibility of no http://www.streetinsider.com/FDA/Moderna+and+Merck+report+sustained+melanoma+treatment+benefits+at+5+years/26579600.html Mon, 01 Jun 2026 08:01:54 -0400 MRK MRNA http://www.streetinsider.com/FDA/Moderna+and+Merck+report+sustained+melanoma+treatment+benefits+at+5+years/26579600.html <p>Moderna Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK) announced five-year follow-up data from their Phase 2b melanoma study showing sustained benefits for their combination cancer treatment. The study evaluated intismeran autogene plus Keytruda versus Keytruda alone in patients with high-risk melanoma following surgery.</p> <p>At a median follow-up of 60.3 months, the combination treatment reduced the risk of cancer recurrence or death by 49% compared to Keytruda alone. The combination also reduced the risk of distant cancer spread or death by 59%. An exploratory analysis showed an encouraging trend toward improved overall survival, though the confidence interval included the possibility of no http://www.streetinsider.com/FDA/Moderna+and+Merck+report+sustained+melanoma+treatment+benefits+at+5+years/26579600.html Mon, 01 Jun 2026 08:01:54 -0400 MRK MRNA http://www.streetinsider.com/Press+Releases/Moderna+and+Merck+Present+5-Year+Data+for+Intismeran+Autogene+in+Combination+With+KEYTRUDA+%28pembrolizumab%29+in+Patients+With+High-Risk+Stage+IIIIV+Melanoma+Following+Complete+Resection+at+the+2026+ASC/26579561.html <p><i><strong>At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA alone</strong></i></p><p><i><strong>Intismeran autogene in combination with KEYTRUDA demonstrated an encouraging trend toward overall survival in an exploratory analysis compared to KEYTRUDA alone (HR=0.471; [95% CI, 0.165-1.345])</strong></i></p> <p><strong id="dateline">CAMBRIDGE, MA AND RAHWAY, NJ / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 1, 2026 / </strong>Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as http://www.streetinsider.com/Press+Releases/Moderna+and+Merck+Present+5-Year+Data+for+Intismeran+Autogene+in+Combination+With+KEYTRUDA+%28pembrolizumab%29+in+Patients+With+High-Risk+Stage+IIIIV+Melanoma+Following+Complete+Resection+at+the+2026+ASC/26579561.html Mon, 01 Jun 2026 08:00:00 -0400 MRK MRNA http://www.streetinsider.com/Press+Releases/Moderna+and+Merck+Present+5-Year+Data+for+Intismeran+Autogene+in+Combination+With+KEYTRUDA+%28pembrolizumab%29+in+Patients+With+High-Risk+Stage+IIIIV+Melanoma+Following+Complete+Resection+at+the+2026+ASC/26579561.html <p><i><strong>At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA alone</strong></i></p><p><i><strong>Intismeran autogene in combination with KEYTRUDA demonstrated an encouraging trend toward overall survival in an exploratory analysis compared to KEYTRUDA alone (HR=0.471; [95% CI, 0.165-1.345])</strong></i></p> <p><strong id="dateline">CAMBRIDGE, MA AND RAHWAY, NJ / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 1, 2026 / </strong>Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as http://www.streetinsider.com/Press+Releases/Moderna+and+Merck+Present+5-Year+Data+for+Intismeran+Autogene+in+Combination+With+KEYTRUDA+%28pembrolizumab%29+in+Patients+With+High-Risk+Stage+IIIIV+Melanoma+Following+Complete+Resection+at+the+2026+ASC/26579561.html Mon, 01 Jun 2026 08:00:00 -0400 MRK MRNA